- Home
- NXTC vs PLUR Comparison
NXTC vs PLUR Comparison
Compare NXTC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- PLUR
- Stock Information
- Founded
- NXTC 2015
- PLUR 2001
- Country
- NXTC United States
- PLUR Israel
- Employees
- NXTC N/A
- PLUR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- PLUR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXTC Health Care
- PLUR Health Care
- Exchange
- NXTC Nasdaq
- PLUR Nasdaq
- Market Cap
- NXTC 13.9M
- PLUR 41.9M
- IPO Year
- NXTC 2019
- PLUR N/A
- Fundamental
- Price
- NXTC $0.50
- PLUR $5.50
- Analyst Decision
- NXTC Strong Buy
- PLUR Strong Buy
- Analyst Count
- NXTC 2
- PLUR 1
- Target Price
- NXTC $3.50
- PLUR $12.00
- AVG Volume (30 Days)
- NXTC 344.4K
- PLUR 63.3K
- Earning Date
- NXTC 07-31-2025
- PLUR 05-13-2025
- Dividend Yield
- NXTC N/A
- PLUR N/A
- EPS Growth
- NXTC N/A
- PLUR N/A
- EPS
- NXTC N/A
- PLUR N/A
- Revenue
- NXTC N/A
- PLUR $1,034,000.00
- Revenue This Year
- NXTC N/A
- PLUR $472.39
- Revenue Next Year
- NXTC N/A
- PLUR $254.29
- P/E Ratio
- NXTC N/A
- PLUR N/A
- Revenue Growth
- NXTC N/A
- PLUR 203.23
- 52 Week Low
- NXTC $0.22
- PLUR $3.33
- 52 Week High
- NXTC $1.82
- PLUR $7.13
- Technical
- Relative Strength Index (RSI)
- NXTC 54.07
- PLUR 60.14
- Support Level
- NXTC $0.42
- PLUR $4.61
- Resistance Level
- NXTC $0.49
- PLUR $5.96
- Average True Range (ATR)
- NXTC 0.04
- PLUR 0.55
- MACD
- NXTC -0.00
- PLUR 0.11
- Stochastic Oscillator
- NXTC 84.89
- PLUR 78.07
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility. It uses its technology in the field of regenerative medicine, food tech and agricultural technology or agtech.